SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

HIVE Digital Technologies Ltd. engages in building a bridge between the digital currency and blockchain sector and traditional capital markets. It operates data centers for computing and mining cryptocurrencies, including Bitcoin and other coins. The firm owns and operates green energy-powered data center facilities in Canada, Sweden, and Iceland. Its project includes Iceland Cryptocurrency Mining. HIVE Digital Technologies was founded on June 24, 1987 and is headquartered in San Antonio, TX.

HIVE Digital Technologies Ltd.

HIVE Digital Technologies Ltd

HIVE Digital Technologies is trending due to its strategic shift towards high-performance computing (HPC) and AI infrastructure, highlighted by a partnership with Bell Canada to build a sovereign AI ecosystem. The community is discussing analyst ratings boosts and expansion into renewable-powered data centers, viewing HIVE as more than just a Bitcoin miner. This transition diversifies HIVE's revenue streams and positions it to capitalize on the growing demand for AI and HPC solutions.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is experiencing volatility as the community debates whether it's consolidating or entering a downtrend, with some citing a recent convertible note offering creating selling pressure. Discussions revolve around potential catalysts, power deals, and comparisons to other AI infrastructure companies. Despite bearish sentiment from some, strong fundamentals and long-term growth prospects are still being emphasized by bulls.

GSI Technology, Inc. engages in the design, development and marketing of memory products primarily for the networking, and telecommunications markets. Its product includes Static Random Access Memory, or SRAM, which incorporated in networking and telecommunications equipment, such as routers, switches, wide area network infrastructure equipment, wireless base stations and network access equipment. It also offers services to the ongoing needs of the military, industrial, test and measurement equipment, automotive and medical markets for SRAMs .The company was founded by Lee-Lean Shu and Robert Yau in March 1995 and is headquartered in Sunnyvale, CA.

GSI Technology Inc

$GSIT is surging following a study highlighting its APU's comparable performance to NVIDIA GPUs with significantly lower energy consumption, sparking community excitement around its potential in AI and edge computing. The community is actively discussing potential buyouts and the possibility of GSIT disrupting the AI chip market. Traders are closely monitoring volume and volatility, anticipating potential breakouts amid the ongoing conversation about energy efficiency in data centers.

Quantum Resistant Ledger is a cryptocurrency based on the Python programming language, aimed at combating future attacks by quantum computers. This cryptocurrency is the brainchild of Peter Waterland who realised that Bitcoin, Ethereum, and other such cryptocurrencies have no protection against future technology. It claims to be a “future-proof” cryptocurrency which enables transactions and decentralized communication while providing protection against classical as well as quantum computer attacks.  The Quantum Resistant Ledger company was founded by Peter Waterland, who found that Bitcoin, as well as Ethereum signatures are susceptible to attacks by powerful quantum computers. His research on quantum computers and signature programs let to the development of this new cryptocurrency, designed to be resistant to the present classical attacks as well as any future quantum computer attacks. Their team is made up of a diverse range of members spread out across the world, including developers (core, blockchain, mobile developers, etc.), analysts, advisors, marketing managers, designers and more.  Quantum Resistant Ledger is the first ever cryptocurrency and the only one in existence as of August 2018, to consider the threat that the future technology of quantum computing poses to cryptocurrencies and their working. It uses a technology specifically designed for post-quantum security, called XMSS, which makes it secure against powerful quantum computers even while using a Proof-of-Stake consensus mechanism. Security against cyber-attacks is a very serious concern in this digital age, especially when you have digital assets whose loss is likely to lead you to bankruptcy.  QRL is the first blockchain technology that provides durability and stability through resistance to quantum computer attacks. The encryption methods used by modern blockchains can become vulnerable to quantum computers over the next ten years. QRL tries to create a blockchain with long-term stability. By using blockchain technology, the QRL platform creates a “ledger” that generates hashes in such a way that it is virtually impenetrable to any type of computer attack.

Quantum Resistant Ledger 

Quantum Resistant Ledger is trending as discussions around quantum computing's potential impact on current blockchain technology intensify, particularly its ability to crack existing encryption. The community highlights QRL's quantum-resistant design from its inception as a key differentiator, positioning it as a hedge against future vulnerabilities in major cryptocurrencies. Recent developments, such as the BitMart listing and mentions in Forbes, are also driving interest.

Aster is a next-generation decentralized exchange offering both Perpetual and Spot trading, designed as a one-stop onchain venue for global crypto traders. It features MEV-free, one-click execution in Simple Mode. Pro Mode adds 24/7 stock perpetuals, Hidden Orders, and grid trading, available across BNB Chain, Ethereum, Solana, and Arbitrum.  Its unique edge lies in the ability to offer liquid-staking tokens (asBNB) or yield-generating stablecoins (USDF) as collateral, unlocking unparalleled capital efficiency. Powered by Aster Chain, a high-performance and privacy-focused L1, and backed by YZi Labs, Aster is building the future of DeFi: fast, flexible, and community-first.  At the heart of this ecosystem is the $ASTER token, a core asset that decentralizes governance, drives growth, rewards participation, and supports long-term sustainability.

ASTERION

ASTERION (ASTER) is trending amid discussions about its recent Robinhood listing and potential for significant price movement. Community members are actively debating entry points, possible manipulation, and whether it can follow similar coins. Technical analysis patterns and exchange volume are also being closely watched.

UTZ Brands, Inc. manufactures, markets, and distributes branded snacking products. It offers a broad range of salty snacks, including potato chips, pretzels, cheese, veggie, other snacks and pork skins. The firm’s brands include Utz, Zapp’s, Golden Flake, Good Health, Boulder Canyon and Hawaiian. The company was founded in 1921 and is headquartered in Hanover, PA.

Utz Brands Inc - Ordinary Shares - Class A

Recent discussions around UTZ Brands are focused on a CEO succession plan and a real estate senior secured term loan. Community members are also discussing the company's fundamentals, growth potential, and the recent price action. Several analysts have updated their price targets and ratings for the stock.

AlphaVest Acquisition Corp. is a blank check company, which engages in effecting a merger, stock exchange, asset acquisition, stock purchase, and reorganization or similar business combination. The company was founded on January 14, 2022 and is headquartered in New York, NY.

AlphaVest Acquisition Corp

AlphaVest Acquisition Corp (ATMV) is trending due to a potential short squeeze, driven by its low float and acquisition news. Community members are actively discussing potential breakouts and price targets, while also weighing the risks associated with low-volume trading and past SEC interventions in similar situations. Reports of a merger with AMC Corporation and PIPE financing may be contributing to the increased attention.

The Mosaic Co. engages in the production and marketing of concentrated phosphate and potash crop nutrients. It operates through the following segments: Phosphates, Potash, and Mosaic Fertilizantes. The Phosphates segment is involved in the ownership and operation of mines and production facilities which produce concentrated phosphate crop nutrients and phosphate-based animal feed ingredients, and processing plants which produce concentrated phosphate crop nutrients. The Potash segment includes mining, processing, and selling potash. The Mosaic Fertilizantes segment focuses on mines, chemical plants, crop nutrient blending and bagging facilities, port terminals, and warehouses. The company was founded on March 25, 2004 and is headquartered in Tampa, FL.

Mosaic Company

Shares of Mosaic are garnering attention as investors assess recent ratings updates and production-related news. Community members are actively discussing averaging down positions and potential options strategies, while also weighing factors such as climate risk, geopolitical factors, and the long-term outlook for fertilizer demand and pricing. Discussions also highlight the stock's valuation, with some seeing it as undervalued relative to peers.

Oxford Lane Capital is an investment company that invests primarily in debt and equity tranches of CLO vehicles.

Oxford Lane Capital Corp

OXLC is trending as investors discuss the potential impact of a reverse stock split and its dividend yield. Community members are weighing whether the company's fundamentals justify the current price, with some pointing to the discount to NAV and ongoing share buybacks as positives, while others express concern over the potential for further price declines and debate the sustainability of the dividend.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CRMD is trending amid discussions about its recent earnings, future growth potential, and a possible short squeeze, with community members actively debating revenue projections and the impact of potential catalysts. Some investors express frustration with the stock's performance despite positive developments and speculate about potential acquisitions, while others highlight the strategic investment in TLPH. The potential influence of institutional investors and CMS policy decisions are also key talking points.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Are You Looking for a Top Momentum Pick? Why Verastem (VSTM) is a Great Choice

Does Verastem (VSTM) have what it takes to be a top stock pick for momentum investors? Let's find out.

Wall Street Analysts Think Verastem (VSTM) Could Surge 68.11%: Read This Before Placing a Bet

The mean of analysts' price targets for Verastem (VSTM) points to a 68.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK-pathway-driven cancers, today announced positive, updated efficacy and...

Verastem (VSTM) Upgraded to Buy: Here's What You Should Know

Verastem (VSTM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Verastem (VSTM) Reports Q2 Loss, Misses Revenue Estimates

Verastem (VSTM) delivered earnings and revenue surprises of +54.12% and -86.36%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Gossamer Bio (GOSS) Reports Q2 Loss, Beats Revenue Estimates

Gossamer Bio (GOSS) delivered earnings and revenue surprises of +5.56% and +155.88%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Verastem (VSTM) Q2 Earnings Expected to Decline

Verastem (VSTM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Tempus AI's 89% Genomics Surge: Will the Momentum Keep Building?  

Shares of Verastem Oncology (VSTM) dropped 19% on Monday despite the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://investor.verastem.com/news-releases/news-release-details/verastem-oncology-announces-updated-data-partner-genfleet">announcing</a> positive updated data from the dose escalation phase of its trial for cancer therapy GFH375, conducted by its partner, GenFleet Therapeutics.In a study in China, GFH375, also known as VS-7375 in the U.S., demonstrated an overall response rate of 52% in patients with pancreatic ductal adenocarcinoma and a response rate of 42% in those with non-small cell lung cancer, the company stated.Verastem stated that data from its partner supports the advancement of its clinical program for VS-7375 in the U.S., which is slated to start in mid-2025.The company is activating sites in the U.S. for VS-7375 to begin enrollment in the trial. The study has the potential to expand globally and will evaluate the safety and efficacy of VS-7375 in patients with advanced, KRAS G12D-mutant solid tumors.The KRAS G12D mutation, a genetic alteration in the KRAS gene, is common in various cancers, particularly pancreatic cancer, colorectal cancer, and lung adenocarcinoma.As part of the collaboration between Verastem and GenFleet, Verastem has development and commercialization rights for the cancer therapy outside the GenFleet markets of mainland China, Hong Kong, Macau, and Taiwan.On Stocktwits, retail sentiment around Verastem rose from ‘bearish’ to ‘bullish’ territory over the past 24 hours while message volume rose from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:627/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_02_at_12_42_50_PM_png_7c68caaf50.webp" alt="VSTM's Sentiment Meter and Message Volume as of 1:00 p.m. ET on June 2, 2025 | Source: Stocktwits" width="627" height="64"><figcaption>VSTM's Sentiment Meter and Message Volume as of 1:00 p.m. ET on June 2, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that the stock could be tanking owing to the Chinese partnership.<stembedurl>https://stocktwits.com/Universaal/message/616509493</stembedurl>According to data from Koyfin, all of the nine analysts covering the stock rate it ‘Buy’ or higher. The stock has an average price target of $15.75, representing an upside of over 150%.<a href="https://stocktwits.com/symbol/VSTM">VSTM stock</a> is down by 6% this year but up by about 55% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/meta-s-push-toward-fully-automated-ads-to-reportedly-debut-by-year-end/chkY2oMRbHJ">Meta’s Push Toward Fully Automated Ads To Reportedly Debut By Year-End</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Verastem Announces Positive Data From Cancer Trial Conducted By Partner: Retail Turns Bullish

In a study conducted in China, GFH375, also known as VS-7375 in the U.S., showed an overall response rate of 52% in patients with pancreatic ductal adenocarcinoma and 42% in those with non-small cell lung cancer.

Equity

VSTM Stock Soars 22% in a Month on Ovarian Cancer Combo Drug Approval

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

Verastem Inc

Will Netflix ($NFLX) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Netflix Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$0.62	--	--	N/A
Q2 '25	-$0.73	-$0.39	46.41%	BEAT
Q1 '25	-$0.70	-$0.96	-37.14%	MISSED
Q4 '24	-$0.83	-$1.33	-60.48%	MISSED
Q3 '24	-$0.74	-$0.60	18.67%	BEAT

VSTM
Verastem Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest VSTM News

VSTMVerastem Inc